Treatment patterns for bullous pemphigoid in older adults: A population-based study
Dermatology Online Journal · 06.07.2026 · 32 (3)
DOI: 10.25251/cwvjt950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Online Journal, online erschienen am 06.07.2026. Verfasst von Abigail Katz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Practice Patterns, Physicians'. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background:Bullous pemphigoid (BP) is a chronic autoimmune blistering disease that disproportionately affects older adults and is associated with substantial morbidity, mortality, and treatment-related risks. Despite an expanding therapeutic landscape, real-world prescribing patterns in this population remain poorly characterized. Objective:To evaluate medication prescribing patterns among older adults with BP and assess the feasibility of using national claims data to characterize treatment exposures relevant to drug safety and risk stratification. Methods:We conducted a retrospective cohort study using Medicare fee-for-service claims data (2016–2020). Adults aged ≥65 years with BP were identified using ICD-10 codes. Prescription drug event (PDE) data were linked to outpatient claims to capture medication use. Treatments were categorized into topical corticosteroids (by potency), oral immunomodulators and antibiotics, and biologic therapies. Descriptive analyses were performed to evaluate prescribing distributions. Results:Among 10,959 patients with BP and 78,468 outpatient claims, we identified 19,663 prescriptions. Oral immunomodulators and antibiotics comprised 67.5% of prescriptions, followed by topical corticosteroids (32.5%) and biologics (0.04%). Prednisone accounted for 62.9% of oral prescriptions, followed by doxycycline (20.2%) and mycophenolate (6.0%). Among topical steroids, medium-potency agents were most common (40.6%), followed by super high-potency (38.2%). Biologic use was rare, with dupilumab accounting for most prescriptions. Conclusion:Systemic corticosteroids remain the predominant therapy for BP in older adults, with substantial variability in topical steroid use and minimal uptake of biologics. These findings highlight gaps in treatment optimization and support the need for risk-informed, steroid-sparing strategies in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- University of Arizona College of Medicine, Phoenix, AZ, USA.
- University of California, San Diego School of Medicine, San Diego, CA, USA.
- University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, HI, USA.
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
- University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR, USA.
Zitieren
APA
Katz, A., Tolson, H. C., Cortes, J. A., Roberts, A. M., Nong, Y., Jeong, C. Y., Ma, E., Chou, P., Yan, M. J., Johnsen, N., Carranza, C., Holland, V. R., Tsugawa, Y., & Armstrong, A. W. (2026). Treatment patterns for bullous pemphigoid in older adults: A population-based study. Dermatology Online Journal, 32(3). https://doi.org/10.25251/cwvjt950
Vancouver
Katz A, Tolson HC, Cortes JA, Roberts AM, Nong Y, Jeong CY, et al. Treatment patterns for bullous pemphigoid in older adults: A population-based study. Dermatology Online Journal. 2026;32(3). doi:10.25251/cwvjt950
BibTeX
@article{Katz2026,
author = {Katz, Abigail and Tolson, Hannah C and Cortes, Julian A and Roberts, Alyssa M and Nong, Yvonne and Jeong, Charlotte Y and Ma, Elaine and Chou, Peichi and Yan, Matthew J and Johnsen, Nicole and Carranza, Camila and Holland, Vanessa R and Tsugawa, Yusuke and Armstrong, April W},
title = {Treatment patterns for bullous pemphigoid in older adults: A population-based study},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {3},
doi = {10.25251/cwvjt950}
}
EUVIMED